Working… Menu
Trial record 1 of 35 for:    Blast Crisis | CML | Germany
Previous Study | Return to List | Next Study

European CML Blast Crisis Register (BlastCrisis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03869502
Recruitment Status : Recruiting
First Posted : March 11, 2019
Last Update Posted : January 29, 2021
Information provided by (Responsible Party):
Annamaria Brioli, University of Jena

Brief Summary:
Multicentric prospective and retrospective register collecting patient with CML blast crisis diagnosed in Germany and Europe

Condition or disease
Chronic Myeloid Leukemia in Myeloid Blast Crisis

Detailed Description:
Since the advent of treatment with tyrosine kinase inhibitors (TKI), the incidence of blast crises has significantly decreased. Nevertheless, about 5% of patients diagnosed with chronic myeloid leukemia (CML) will evolve into a blast phase at some point during the course of their disease. Furthermore, despite the advances made in CML treatment, outcome of patients with blast crises are still dismal. Due to the rarity of this condition clinical trials are challenging, and collaboration between researchers both at national and international level is needed to collect a meaningful number of data.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 250 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 1 Day
Official Title: European CML Blast Crisis Register
Actual Study Start Date : October 25, 2018
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2024

Primary Outcome Measures :
  1. Overall survival [ Time Frame: through study completion in 2024 ]
    how many patients survive after a blast crisis event

Secondary Outcome Measures :
  1. Rate of hematologic response to treatment [ Time Frame: through study completion in 2024 ]
    how many patients have a hematologic response to the local standard Treatment after a blast crisis event

  2. Rate of molecular response to treatment [ Time Frame: through study completion in 2024 ]
    how many patients have a molecular response to the local standard Treatment after a blast crisis event

  3. Rate of blast crises in Europe in the era of TKI treatment [ Time Frame: through study completion in 2024 ]
    how many patients have blast crisis events compared to all treated CML-patients in the trial centers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with CML Blast crisis, either newly diagnosed or as evolution of a CML in chronic phase

Inclusion Criteria:

  • Age >18 years
  • Diagnosis of BCR-ABL positive CML blast crisis according to the WHO criteria:

    • Blasts 20% or more of peripheral blood white cells or bone marrow cells or
    • Extramedullary blast proliferation or
    • Large foci or clusters of blasts in bone marrow biopsy

Exclusion Criteria:

  • Lack of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03869502

Layout table for location contacts
Contact: Annamaria Brioli, PhD MD +49 36419324576
Contact: Christian Fabisch, Dr. +49 36419396670

Layout table for location information
Masaryk University Hospital Brno Recruiting
Brno, Czechia, 62500
Contact: Jiri Mayer, Prof. Dr.         
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Recruiting
Dresden, Germany, 01307
Contact: Christoph Röllig, PD Dr.         
Universitätsklinikum Essen Recruiting
Essen, Germany, 45147
Contact: Joachim R. Göthert, Dr.         
University Hospital Jena Recruiting
Jena, Germany, 07747
Contact: Annamaria Brioli, PhD MD    +49 36419324576   
Universitätsklinikum Leipzig AöR Recruiting
Leipzig, Germany, 04103
Contact: Georg-Nikolaus Franke, Dr.         
Universitätsmedizin Mannheim Recruiting
Mannheim, Germany, 68169
Contact: Susanne Saussele, Prof. Dr.         
Universitaetsklinikum Muenster Recruiting
Münster, Germany, 48149
Contact: Matthias Stelljes, Prof. Dr.         
Russian Federation
I. P. Pavlov First St. Petersburg State Medical University Recruiting
Saint Petersburg, Russian Federation, 197022
Contact: Elena Morozova, PhD Dr.         
National Research Center for Radiation Medicine Recruiting
Kiev, Ukraine, 02000
Contact: Iryna Dyagil, Dr.         
Sponsors and Collaborators
University of Jena
Layout table for investigator information
Principal Investigator: Annamaria Brioli, PhD MD Univerity of Jena
Additional Information:

Layout table for additonal information
Responsible Party: Annamaria Brioli, Principal Investigator, University of Jena Identifier: NCT03869502    
Other Study ID Numbers: BlastCrisis
First Posted: March 11, 2019    Key Record Dates
Last Update Posted: January 29, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: A joint publication is planned. But no data of trial Centers will be shared with the other trial centers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Blast Crisis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Cell Transformation, Neoplastic
Neoplastic Processes
Pathologic Processes